Resource use associated with topiramate in migraine prophylaxis

American Journal of Health-System Pharmacy

Volumn 64, Issue 14, 2007, Pages 1483-1491

  Feliu, Anthony L ^a   Rupnow, Marcia F T ^b   Blount, Angela ^c   Boccuzzi, Stephen J ^a   Vermilyea, James ^d  

^a PharMetrics Inc   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^d QualityMetric Incorporated   (United States)

Author keywords

Analgesics and antipyretics; Anticonvulsants; Antiinflammatory agents; Dosage; Health care; Hospitals; Migraine; Topiramate

Indexed keywords

ALMOTRIPTAN; AMITRIPTYLINE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYPROHEPTADINE; ELETRIPTAN; ERGOTAMINE DERIVATIVE; FROVATRIPTAN; NARATRIPTAN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RIZATRIPTAN; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; ZOLMITRIPTAN;

ADULT; AGED; ARTICLE; DEMOGRAPHY; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; EMERGENCY WARD; FEMALE; HEADACHE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 34447581246     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060590     Document Type: Article

References (21)

1. Kobak KA, Katzelnick DJ, Sands G et al. Prevalence and burden of illness in migraine in managed care patients. J Manag Care Pharm. 2005; 11:124-36.
2. Stewart WF, Lipton RB, Celentano DD et al. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992; 267:64-9.
3. National Headache Foundation. www.headaches.org/consumer/topicsheets/ migraine.html (accessed 2006 Sep 12).
4. Lipton RB, Stewart WF, Diamond S et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001; 41:646-57.
5. Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence. A review of population-based studies. Neurology. 1995; 44(suppl 4):S17-23.
6. Hawkins K, Wang S, Rupnow M. Indirect cost of migraine in the United States. J Occup Environ Med. 2007; 49:368-74.
7. Hawkins K, Rupnow MF, Wang S. Direct cost burden of migraine among members of U.S. employers. Headache. 2006; 46:868. Abstract F68.
8. Diamond S, Bigal ME, Silberstein S et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007; 47:355-63.
9. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache. 2003; 43:171-8.
10. Etemad LR, Yang W, Globe D et al. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm. 2005; 11:137-44.
11. Ramadan NM, Silberstein SD, Freitag FG et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacologic management for prevention of migraine. 2000. www.aan.com/professionals/practice/pdfs/gl0090.pdf (accessed 2006 Sep 12).
12. Snow V, Weiss K, Wall EM et al., Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med. 2002; 137:840-9.
13. Brandes JL, Saper JR, Diamond M et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004; 291:965-73.
14. Silberstein SD, Neto W, Schmitt J et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004; 61:490-5.
15. Diener HC, Tfelt-Hansen P, Dahlöf C et al. Topiramate in migraine prophylaxis: results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004; 251:943-50.
16. Diamond M, Dahlöf C, Papadopoulos G et al. Topiramate improves health-related quality of life when used to prevent migraine. Headache. 2005; 45:1023-30.
17. Silberstein SD, Loder E, Forde G et al. The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin. 2006; 22:1021-9.
18. Brandes JL, Kudrow DB, Rothrock JF et al. Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clin Proc. 2006; 81:1311-9.
19. National Guideline Clearinghouse. Treatment of primary headache: preventive treatment of migraine. Standards of care for headache diagnosis and treatment. www.guideline.gov/summary/summary.aspx?doc_id=6580 (accessed 2006 Oct 30).
20. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993; 46:1075-9.
21. Rapoport A, Mauskop A, Diener HC et al. Long-term migraine prevention with topiramate: open-label extension of pivotal trials. Headache. 2006; 46:1151-60.